14 results on '"Schach, Kim"'
Search Results
2. Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomy
3. Clinicopathologic factors, treatment patterns, and outcomes in micropapillary urothelial carcinoma (UC).
4. Immunological correlates of response to immune checkpoint inhibitors (ICI) in metastatic urothelial carcinoma (mUC) patients (pts).
5. Serial changes in PD1/PDL1 expression in metastatic urothelial carcinoma (mUC) patients (pts) treated with immune checkpoint blockade (CPB).
6. Myeloid derived suppressor cells (MDSC) correlate with inflammatory biomarkers in metastatic urothelial carcinoma (mUC)
7. Myeloid derived suppressor cells (MDSC) and inflammatory biomarkers in metastatic urothelial carcinoma (mUC).
8. Real-world experience with atezolizumab (atezo) in advanced urothelial cancer (UC).
9. Serial measurements of myeloid derived suppressor cells (MDSC) in metastatic urothelial carcinoma (mUC) patients (pts) treated with immune checkpoint inhibitors (CI).
10. Evaluation of patient (Pt), treatment, and prognostic factors in urinary tract adenocarcinoma.
11. PD1, PDL1, PDL2 tumor tissue (TT) expression as predictors of response to neoadjuvant chemotherapy (NAC) and outcome in bladder cancer (BC).
12. Patient/treatment characteristics and prognostic factors in small-cell bladder cancer (SCBC).
13. Evaluation of blood and tissue myeloid derived suppressor cells (MDSC), clinicopathologic factors, and pathologic response in urothelial carcinoma (UC).
14. Correlation of myeloid derived suppressor cell (MDSC) populations with clinicopathologic features in urothelial carcinoma (UC).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.